F8

Sanofi said that the launch of Dupixent in COPD is off to a promising start. The company called 2025 an 'inflection year," for uptake of the product in the indication. As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary disorder (COPD).So far, so good.After gaining FDA approval in the indication in September of last year, the company is on a “record-setting pace,” as it relates to coverage, according to Brian Foard, Sanofi’s head of specialty care, speaking at the company’s first quarter conference call.Medicare and commercial coverage are at 90% and 88% respectively, Foard said, adding that “as you look at initiations we’re seeing, it’s our most rapid respiratory initiation launch so far.”COPD represents a significant opportunity for Sanofi and its U.S. drug partner Regeneron as Dupixent is the first biologic approved for the condition, which is the fourth-leading cause of death in the world. With many patients having “resigned themselves to their condition,” according to Sanofi CEO Paul Hudson, the company is busy educating pulmonologists and patients about the benefits of the treatment.Sanofi has launched Dupixent for COPD in eight countries, said Hudson, who added that 2025 will be the "inflection year," for the treatment in the indication. Last week, the FDA approved Dupixent in its seventh indication—the hives disorder chronic spontaneous urticaria (CSU). The company expects another nod this year for Dupixent to treat the skin disease bullous pemphigoid (BP).The company reported Q1 sales of Dupixent at 3.5 billion euros ($4 billion), which was an impressive increase of 20% year over year. In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023.Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance. The company racked up sales of 9.9 billion euros ($11.3 billion) in the first quarter, which was a 10% increase year-over-year. Also playing a role was hemophilia A treatment Altuviiio, which made a 100% leap in sales to 251 million euros ($285 million) and “has the potential to become our next blockbuster this year,” Hudson said.Hudson added that Altuviiio, which was approved in early 2023, is “benefiting from patient switches,” as they move away from factor VIII replacement medicines, such as the company’s aging Eloctate, which saw a 21% decline in sales to 70 million euros ($80 million) in the quarter.Meanwhile, sales of Sanofi’s factor VIX replacement treatment Alprolix—which was approved for hemophilia B patients three months before Eloctate in 2014—grew by 20% to 160 million euros ($182 million).

STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of Altuvoct® (efanesoctocog alfa) treatment for haemophilia A, including updates on patients' joint health and surgical outcomes in patients. "At WFH 2025 CCS, Sobi will present highlights from the XTEND phase 3 program and discuss the new treatment paradigm with FVIII levels in the non-haemophilia range. Sharing these clinical outcomes with the wider haemophilia community will help to ensure the latest treatment approaches are widely known and understood," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi. Key data to be presented at WFH 2025 Comprehensive Care Summit, Dubai, UAE Altuvoct® (efanesoctocog alfa) About efanesoctocog alfa Efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is a novel and significant part of the week factor VIII therapy. It has the potential to deliver near-normal factor activity levels for significant parts of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. It was approved as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US in February 2023. About the Sobi and Sanofi collaboration Sobi and Sanofi collaborate on the development and commercialisation of Alprolix® and Elocta®/Eloctate®. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, referred to as ALTUVIIIO™ in the USA and ALTOVUCT in Europe. An investigational factor VIII therapy with the potential to provide high sustained factor activity levels with once-weekly dosing for people with haemophilia A. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. Sobi® Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East and Asia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube. Contact For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Pfizer’s Hympavzi (marstacimab) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat haemophilia A or B in adult and paediatric patients. The drug has been authorised to prevent or reduce bleeding episodes in patients ages 12 years and older who weigh at least 35kg and have severe haemophilia A without factor VIII inhibitors or severe haemophilia B without factor IX inhibitors. More than 11,800 people were living with haemophilia A or B in the UK in 2023/2024, including 2,700 with severe disease. The genetic blood disorders primarily affect males and are caused by a clotting factor deficiency. Alongside episodes of excessive and prolonged bleeding, haemophilia patients can experience spontaneous bleeding in their joints and muscles without having had an injury, potentially leading to joint damage. Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI, a naturally occurring protein that prevents blood from clotting too much. This promotes the formation of thrombin, an enzyme critical in blood clotting. The MHRA’s decision on the drug was supported by results from the late-stage BASIS trial, in which the annualised bleeding rate for treated bleeds was 7.85 for routine factor-based prophylaxis during a six‑month observation period and 5.08 for Hympavzi prophylaxis during a 12‑month active treatment period. Seema Patel, medical director specialty care, Pfizer UK, described the authorisation as “an important step towards providing eligible patients with a new treatment option”. Hympavzi is now being evaluated by the National Institute for Health and Care Excellence and Scottish Medicines Consortium for use on the NHS. “We will continue working with reimbursement agencies across the UK with the aim of making [Hympavzi] available on the NHS,” Patel said. Haemophilia is a key therapeutic area for Pfizer and the company has a significant presence in the field. In July last year, its haemophilia B gene therapy was granted conditional marketing authorisation by the European Commission to treat adults with severe and moderately severe cases. In the same month, the company shared positive top-line results from a late-stage study of its investigational haemophilia A gene therapy giroctocogene fitelparvovec, which is being developed as part of a collaboration agreement between Pfizer and Sangamo Therapeutics.